Hanover - Delayed Quote EUR
Swedish Orphan Biovitrum AB (B6E.HA)
27.86
-0.12
(-0.43%)
As of 8:01:08 AM GMT+2. Market Open.
Loading Chart for B6E.HA
- Previous Close
27.98 - Open
27.86 - Bid 28.32 x --
- Ask 28.36 x --
- Day's Range
27.86 - 27.86 - 52 Week Range
22.06 - 30.52 - Volume
0 - Avg. Volume
1 - Market Cap (intraday)
-- - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jul 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Recent News: B6E.HA
View MorePerformance Overview: B6E.HA
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
B6E.HA
1.38%
OMX Stockholm 30 Index (^OMX)
1.55%
1-Year Return
B6E.HA
13.62%
OMX Stockholm 30 Index (^OMX)
3.93%
3-Year Return
B6E.HA
50.61%
OMX Stockholm 30 Index (^OMX)
25.37%
5-Year Return
B6E.HA
25.23%
OMX Stockholm 30 Index (^OMX)
65.61%
Compare To: B6E.HA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
27.86
-0.43%
Mkt Cap EUR -
Industry Drug Manufacturers—Specialty & Generic
26.46
+2.16%
Mkt Cap EUR 4.826B
Industry Drug Manufacturers—Specialty & Generic
3.6200
+2.55%
Mkt Cap EUR 4.009B
Industry Drug Manufacturers—Specialty & Generic
4.1600
+3.48%
Mkt Cap EUR 4.011B
Industry Drug Manufacturers—Specialty & Generic
27.17
0.00%
Mkt Cap 5.501B
Industry Drug Manufacturers—Specialty & Generic
10,850.00
+115.28%
Mkt Cap HUF 3.749T
Industry Drug Manufacturers—Specialty & Generic
Statistics: B6E.HA
View MoreValuation Measures
As of 5/7/2025
Market Cap
9.39B
Enterprise Value
10.59B
Trailing P/E
26.05
Forward P/E
21.19
PEG Ratio (5yr expected)
1.66
Price/Sales (ttm)
3.93
Price/Book (mrq)
2.62
Enterprise Value/Revenue
4.39
Enterprise Value/EBITDA
12.27
Financial Highlights
Profitability and Income Statement
Profit Margin
--
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--